Atlas Trials

Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer

Clinical trial NCT04068974 · UNKNOWN

Trial details

NCT number
NCT04068974
Sponsor
Peking Union Medical College Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Recurrent Platinum-resistant Ovarian Cancer
Start date
2019-10-28
Primary completion
2021-06-30
Enrollment
28

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.